Health Care · Services-Health Services · Nasdaq · CIK 1818331 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $63.69Day +2.92%Mkt cap $1.9B1Y −30.6%Off 52W high −62.7%Vol (1Y) 84.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 887 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest19.6% of sh out |
| Days to cover8.4d |
| 13F net flow (QoQ)+4.09% |
| Top-10 13F concentration47.3% |
| Next report (est.)2026-08-03 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$442.7M |
| Earnings (TTM)-$77.8M |
| ROE−7.6% |
| Net margin−4.9% |
| ROIC−4.4% |
| Debt / equity0.17× |
| Sales growth 3Y22.1% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−51.0% |
| 1Y−30.6% |
| 3Y+759.4% |
| Since incept. (ann.)+61.9% |
Total return through 2026-07-29 · series begins 2023-01-10. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)84.3% |
| Ann. volatility (3Y)111.7% |
| Sharpe (1Y)0.15 |
| Sharpe (3Y)1.21 |
| Max drawdown (1Y)−79.4% |
| Max drawdown (3Y)−83.7% |
| Beta (3Y vs SPY)1.27 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Corvex Management LP | 3.2M | $207M | 10.87% | +5.5% |
| Casdin Capital, LLC | 3.0M | $193M | 10.13% | +0.0% |
| BlackRock, Inc. | 1.6M | $100M | 5.22% | −0.6% |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 1.4M | $88M | 4.61% | +34.5% |
| GOLDMAN SACHS GROUP INC | 1.3M | $86M | 4.50% | +9.4% |
| ARK Investment Management LLC | 1.3M | $85M | 4.46% | +119.1% |
| VANGUARD CAPITAL MANAGEMENT LLC | 858,583 | $55M | 2.89% | new |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 775,269 | $50M | 2.61% | −4.2% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 105.3% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 4,222,620 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-04 | −$2.16 | — | $102.3M | +17.4% |
| 2025-12-31 | 2026-02-23 | — | — | $121.0M | +26.5% |
| 2025-09-30 | 2025-10-28 | −$0.27 | — | $116.7M | +51.9% |
| 2025-06-30 | 2025-07-29 | $0.36 | — | $102.7M | +45.6% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-03 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Gene Dx 99% · All Other Segments 1%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
